Author: Dussupt, Vincent; Sankhala, Rajeshwer S.; Gromowski, Gregory D.; Donofrio, Gina; De La Barrera, Rafael A.; Larocca, Rafael A.; Zaky, Weam; Mendez-Rivera, Letzibeth; Choe, Misook; Davidson, Edgar; McCracken, Michael K.; Brien, James D.; Abbink, Peter; Bai, Hongjun; Bryan, Aubrey L.; Bias, Candace Hope; Berry, Irina Maljkovic; Botero, Nubia; Cook, Tanya; Doria-Rose, Nicole A.; Escuer, Ariadna Grinyo i; Frimpong, Justice Akuoku; Geretz, Aviva; Hernandez, Mayda; Hollidge, Bradley S.; Jian, Ningbo; Kabra, Kareem; Leggat, David J.; Liu, Jinyan; Pinto, Amelia K.; Rutvisuttinunt, Wiriya; Setliff, Ian; Tran, Ursula; Townsley, Samantha; Doranz, Benjamin J.; Rolland, Morgane; McDermott, Adrian B.; Georgiev, Ivelin S.; Thomas, Rasmi; Robb, Merlin L.; Eckels, Kenneth H.; Barranco, Elizabeth; Koren, Michael; Smith, Darci R.; Jarman, Richard G.; George, Sarah L.; Stephenson, Kathryn E.; Barouch, Dan H.; Modjarrad, Kayvon; Michael, Nelson L.; Joyce, M. Gordon; Krebs, Shelly J.
Title: Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor Cord-id: lwvb6dxc Document date: 2020_2_3
ID: lwvb6dxc
Snippet: Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs. (1–3)). Despite advances in vaccine development, it remains unclear how ZIKV vaccination affects immune responses in humans with prior flavivirus immunity. Here we show that a single-dose immunization of ZIKV purified inactivated
Document: Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs. (1–3)). Despite advances in vaccine development, it remains unclear how ZIKV vaccination affects immune responses in humans with prior flavivirus immunity. Here we show that a single-dose immunization of ZIKV purified inactivated vaccine (ZPIV)(4–7) in a dengue virus (DENV)-experienced human elicited potent cross-neutralizing antibodies to both ZIKV and DENV. Using a unique ZIKV virion-based sorting strategy, we isolated and characterized multiple antibodies, including one termed MZ4, which targets a novel site of vulnerability centered on the Envelope (E) domain I/III linker region and protects mice from viremia and viral dissemination following ZIKV or DENV-2 challenge. These data demonstrate that Zika vaccination in a DENV-experienced individual can boost pre-existing flavivirus immunity and elicit protective responses against both ZIKV and DENV. ZPIV vaccination in Puerto Rican individuals with prior flavivirus experience yielded similar cross-neutralizing potency after a single vaccination, highlighting the potential benefit of ZIKV vaccination in flavivirus-endemic areas.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date